摘要:
A dry connection prefabricated assembly steel-concrete composite beam, comprising a steel beam (400), a concrete slab (300) composed of steel bars (301) and concrete, a steel plate connector (100) composed of a steel plate (101), shear connection pieces (102) and connection rods (103), and a pair of inter-plate connection pieces respectively composed of an upper connection plate (501), a lower connection plate (502), a horizontal connection plate (503), a triangular reinforcing steel plate (504) and first and second shear connection pieces (505, 507). An upper surface of each horizontal connection plate (503) is vertically connected to the upper connection plate (501) and the first shear connection pieces (505), a lower surface is vertically connected to the lower connection plate (502), the triangular reinforcing steel plate (504) is welded between a lower surface of the horizontal connection plate (503) and a side surface of the lower connection plate, and one side surface of the upper connection plate (501) is horizontally connected to the second shear connection pieces (507). Both ends of the steel bars (301), which are laterally preset within the concrete slab (300), are provided with screw threads, and the screw thread ends of the steel bars respectively pass through bolt holes (509) and work holes (5010) arranged at upper ends of the upper connection plates (501) to be fixedly connected via screw nuts (302). The composite beam reduces on-site workload, and facilitates disassembly.
摘要:
PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.
摘要:
The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts and solvates thereof, wherein A, X, R1, R3 and R4 are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals with administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.
摘要:
The present invention is directed to compounds of Formula (I), and to salts thereof, their synthesis, and their use as PI3-Kα inhibitors and/or PI3-Kα/mTOR dual inhibitors.
摘要:
A motor vehicle climate control system that utilizes a door to selectively open and close an inlet formed in a housing of the climate control system. The housing includes a wall having a seal surface. The seal surface is spaced outwardly from an inner surface of the wall. A seal member, typically attached to the door used to open and close the inlet, contacts the seal surface when the door is placed in a position to close the inlet.
摘要:
Ligand inhibitors for increasing levels of free corticotropin-releasing factor (CRF) in the brain. Such ligand inhibitors cause release of CRF from the CRF/CRF-binding protein complex. Administration of the ligand inhibitors provide improvement in learning and memory, result in decreased food intake and/or provide treatment for diseases associated with low levels of CRF in the brain, notably Alzheimer's disease. The ligand inhibitor is represented by the formula: ##STR1##
摘要:
The present invention is directed to compounds of Formula (I), and to salts thereof, their synthesis, and their use as PI3-Kα inhibitors and/or PI3-Kα/mTOR dual inhibitors.
摘要:
The present invention generally relates to an HVAC door and method of use for an HVAC system in a vehicle, and more specifically to an airflow distribution door for use in a vehicle climate control system configured to suppress flutter of the door.
摘要:
PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.
摘要:
The present invention provides various methods for increasing beta cell mass. In certain embodiments, such methods include steps of administering to a subject an effective amount of: (a) SDF1, a polypeptide having amino acid sequence substantially homologous thereto, or a fragment thereof capable of increasing beta cell survival; and (b) GLP-1 Exendin-4, a polypeptide having amino acid sequence substantially homologous to GLP-1 or Exendin-4, or a fragment of GLP-1 or Exendin-4 capable of promoting beta cell proliferation, whereby beta cell mass is increased in the subject.